Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | TNF | P01375 | 1/20 | 0.73 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.69 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.69 |
| ▸ | GALR3 | O60755 | 2/20 | 0.68 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 1/20 | 0.65 |
| ▸ | PTAFR | P25105 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3500155 | 0.99 | HDAC1 (0.73) | HDAC1HDAC6TNFAGTR1AGTR2 | |
| SCHEMBL9302226 | 0.90 | HDAC1 (0.73) | HDAC1HDAC6TNFAGTR1AGTR2 | |
| SCHEMBL3668391 | 0.85 | HDAC1 (0.73) | HDAC1HDAC6TNFGALR3NR2F2 | |
| SCHEMBL12850475 | 0.85 | HDAC1 (1.00) | HDAC1HDAC6TNFGALR3NR2F2 | |
| SCHEMBL14000450 | 0.85 | HDAC1 (0.81) | HDAC1HDAC6TNFGALR3NR2F2 | |
| SCHEMBL231295 | 0.85 | TNF (1.00) | HDAC1HDAC6TNFGALR3NR2F2 | |
| SCHEMBL6169195 | 0.85 | TNF (0.62) | HDAC1HDAC6TNFAGTR1AGTR2 | |
| SCHEMBL2884309 | 0.85 | ALDH1A1 (0.74) | AGTR1AGTR2PPARGDRD2TBXA2R | |
| SCHEMBL28989060 | 0.84 | AGTR1 (0.67) | HDAC1HDAC6AGTR1AGTR2PPARG | |
| SCHEMBL9256992 | 0.84 | HDAC1 (0.68) | HDAC1HDAC6TNFAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | disclosed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| EP-0734386-B1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0734386-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | Abbott Laboratories (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5486525-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995016687-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LABORATORIES (US) | 1995-06-22 | — | — | WO | disclosed |
| WO-1990009997-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036452-A1 | TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | HDAC1 1100/4885HDAC6 2016/4885TNF 4688/4885 |
| US-20110281871-A1 | TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | HDAC1 1100/4885HDAC6 2016/4885TNF 4688/4885 |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HDAC1 482/4885HDAC6 425/4885TNF 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.